HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (NasdaqGM:NTEC) today announced that it received a milestone payment from Novo Nordisk A/S (NYSE:NVO) under a license agreement for the use of Neose’s GlycoPEGylation™ technology to develop a next-generation version of recombinant Factor VIII. Novo Nordisk continues to fully fund Neose’s development work for Factor VIII.
